Apixaban prices are heading back downwards in the UK after months of increases, according to the latest figures from market researcher WaveData.
Apixaban Prices Begin To Correct After Months Of UK Rises
Pricewatch UK – October 2024
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
More from Pricewatch UK
• By
In a month that saw the average prices of five generic presentations more than double in the UK, WaveData’s figures showed trimethoprim leading the rises with an enormous price increase in February, as several products bounced back from declines in the previous month.
• By
Vardenafil led the steepest generic price rises in the UK in January, with the average cost of one presentation of the erectile dysfunction treatment more than trebling.
• By
UK prices for gabapentin almost trebled in December, according to the latest figures from WaveData.
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
More from Generics Bulletin
• By
With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.